107 related articles for article (PubMed ID: 12029153)
1. Primary replication of a recombinant Sendai virus vector in macaques.
Kano M; Matano T; Kato A; Nakamura H; Takeda A; Suzaki Y; Ami Y; Terao K; Nagai Y
J Gen Virol; 2002 Jun; 83(Pt 6):1377-1386. PubMed ID: 12029153
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the immunogenicity of replication-competent V-knocked-out and replication-defective F-deleted Sendai virus vector-based vaccines in macaques.
Takeda A; Igarashi H; Kawada M; Tsukamoto T; Yamamoto H; Inoue M; Iida A; Shu T; Hasegawa M; Matano T
Vaccine; 2008 Dec; 26(52):6839-43. PubMed ID: 18930099
[TBL] [Abstract][Full Text] [Related]
3. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies.
Moriya C; Horiba S; Kurihara K; Kamada T; Takahara Y; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Matano T
Vaccine; 2011 Nov; 29(47):8557-63. PubMed ID: 21939708
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of repeated Sendai viral vector vaccination in macaques.
Kurihara K; Takahara Y; Nomura T; Ishii H; Iwamoto N; Takahashi N; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Moriya C; Matano T
Microbes Infect; 2012 Nov; 14(13):1169-76. PubMed ID: 22884717
[TBL] [Abstract][Full Text] [Related]
5. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus.
Kato M; Igarashi H; Takeda A; Sasaki Y; Nakamura H; Kano M; Sata T; Iida A; Hasegawa M; Horie S; Higashihara E; Nagai Y; Matano T
Vaccine; 2005 May; 23(24):3166-73. PubMed ID: 15837216
[TBL] [Abstract][Full Text] [Related]
6. Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques.
Moriya C; Horiba S; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Matano T
Biochem Biophys Res Commun; 2008 Jul; 371(4):850-4. PubMed ID: 18466766
[TBL] [Abstract][Full Text] [Related]
7. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
8. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model.
Takeda A; Igarashi H; Nakamura H; Kano M; Iida A; Hirata T; Hasegawa M; Nagai Y; Matano T
J Virol; 2003 Sep; 77(17):9710-5. PubMed ID: 12915583
[TBL] [Abstract][Full Text] [Related]
9. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M
J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905
[TBL] [Abstract][Full Text] [Related]
10. Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.
Izumi Y; Ami Y; Matsuo K; Someya K; Sata T; Yamamoto N; Honda M
J Virol; 2003 Dec; 77(24):13248-56. PubMed ID: 14645581
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the expression and immunogenicity of wild-type and sequence-modified HIV-1 gag genes in a recombinant Sendai virus vector.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Li H; Li Z; Zhong R; Zeng Y
Curr HIV Res; 2010 Apr; 8(3):199-206. PubMed ID: 20158459
[TBL] [Abstract][Full Text] [Related]
12. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.
Buffa V; Negri DR; Leone P; Borghi M; Bona R; Michelini Z; Compagnoni D; Sgadari C; Ensoli B; Cara A
Viral Immunol; 2006; 19(4):690-701. PubMed ID: 17201664
[TBL] [Abstract][Full Text] [Related]
14. Development of an AIDS vaccine using Sendai virus vectors.
Ishii H; Matano T
Vaccine; 2015 Nov; 33(45):6061-5. PubMed ID: 26232346
[TBL] [Abstract][Full Text] [Related]
15. Antibody-secreting cells specific for simian immunodeficiency virus antigens in lymphoid and mucosal tissues of immunized macaques.
Bergmeier LA; Mitchell EA; Hall G; Cranage MP; Cook N; Dennis M; Lehner T
AIDS; 1998 Jul; 12(10):1139-47. PubMed ID: 9677162
[TBL] [Abstract][Full Text] [Related]
16. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.
Matano T; Kano M; Nakamura H; Takeda A; Nagai Y
J Virol; 2001 Dec; 75(23):11891-6. PubMed ID: 11689672
[TBL] [Abstract][Full Text] [Related]
17. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system.
Evans DT; Chen LM; Gillis J; Lin KC; Harty B; Mazzara GP; Donis RO; Mansfield KG; Lifson JD; Desrosiers RC; Galán JE; Johnson RP
J Virol; 2003 Feb; 77(4):2400-9. PubMed ID: 12551977
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.
Casimiro DR; Wang F; Schleif WA; Liang X; Zhang ZQ; Tobery TW; Davies ME; McDermott AB; O'Connor DH; Fridman A; Bagchi A; Tussey LG; Bett AJ; Finnefrock AC; Fu TM; Tang A; Wilson KA; Chen M; Perry HC; Heidecker GJ; Freed DC; Carella A; Punt KS; Sykes KJ; Huang L; Ausensi VI; Bachinsky M; Sadasivan-Nair U; Watkins DI; Emini EA; Shiver JW
J Virol; 2005 Dec; 79(24):15547-55. PubMed ID: 16306625
[TBL] [Abstract][Full Text] [Related]
19. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
20. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
McKenna PM; Koser ML; Carlson KR; Montefiori DC; Letvin NL; Papaneri AB; Pomerantz RJ; Dietzschold B; Silvera P; McGettigan JP; Schnell MJ
J Infect Dis; 2007 Apr; 195(7):980-8. PubMed ID: 17330788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
